Everest Medicines Announces Termination of Collaboration Agreements with Providence
Everest Medicines is a biopharmaceutical company focused on developing, manufacturing and commercializing transformative pharmaceutical products and vaccines that…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
19 Feb 24
Everest Medicines is a biopharmaceutical company focused on developing, manufacturing and commercializing transformative pharmaceutical products and vaccines that…
16 Feb 24
Under the agreement, the firms intend to combine Xyphos' ACCEL technology and Kelonia's iGPS to create in vivo…
16 Feb 24
The partnership will combine Intellia's patented CRISPR-based gene editing platform with ReCode's Selective Organ Targeting (SORT) lipid nanoparticle…
15 Feb 24
The collaboration is focused on evaluating MEK inhibitor trametinib in combination with pan-RAF inhibitor naporafenib in SEACRAFT-1 and…
15 Feb 24
NM49 is a multi-specific antibody designed to activate tumour associated macrophage phagocytosis to treat cancers and identified through…
15 Feb 24
The effectiveness of iloprost in treating severe frostbite was determined by an open-label, controlled trial in which none…
15 Feb 24
Brii Biosciences also agreed to acquire manufacturing capabilities and certain related assets and will also remove payment obligations…
15 Feb 24
Elsie will receive a license payment and potential development and commercial milestones
14 Feb 24
The Phase 2 KOURAGE trial will assess Auxora with associated acute hypoxemic respiratory failure in the first half…
14 Feb 24
Attacks treated with both 300mg and 600mg of sebetralstat achieved the primary endpoint of symptom relief significantly faster…